论文部分内容阅读
经皮冠脉介入治疗(PCI)后再狭窄是影响冠心痛介入治疗后期疗效的主要原因。再狭窄发生的因素可能与高血压、糖尿病、高脂血症、吸烟、A型性格、血液系统某些疾病等全身因素,及血管、血液、支架及介入治疗相关技术等局部因素有关。本文介绍纤维蛋白原(Fg)研究进展及其对再狭窄的影响。
Restenosis after percutaneous coronary intervention (PCI) is the main reason that affects the efficacy of percutaneous coronary intervention after percutaneous coronary intervention. Restenosis may occur with factors such as systemic factors such as hypertension, diabetes, hyperlipidemia, smoking, type A personality, certain diseases of the blood system, and local factors such as blood vessels, blood vessels, stents and interventional techniques. This article describes the research progress of fibrinogen (Fg) and its effect on restenosis.